Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$17.11
-2.7%
$21.01
$15.85
▼
$30.96
$2.96B0.871.82 million shs1.90 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$60.41
-1.6%
$58.42
$49.26
▼
$70.98
$11.70B0.212.16 million shs5.97 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$91.35
-1.8%
$113.53
$61.22
▼
$134.00
$10.41B0.921.99 million shs1.46 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$9.95
-5.9%
$15.89
$9.89
▼
$29.23
$7.96B-1.494.84 million shs7.16 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-1.35%-3.03%-13.94%-40.37%-23.85%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-0.02%+8.32%+8.82%-7.92%+16.86%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.88%-7.58%-25.19%-13.99%+32.44%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.67%-29.86%-34.31%-19.68%-36.17%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$17.11
-2.7%
$21.01
$15.85
▼
$30.96
$2.96B0.871.82 million shs1.90 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$60.41
-1.6%
$58.42
$49.26
▼
$70.98
$11.70B0.212.16 million shs5.97 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$91.35
-1.8%
$113.53
$61.22
▼
$134.00
$10.41B0.921.99 million shs1.46 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$9.95
-5.9%
$15.89
$9.89
▼
$29.23
$7.96B-1.494.84 million shs7.16 million shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-1.35%-3.03%-13.94%-40.37%-23.85%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-0.02%+8.32%+8.82%-7.92%+16.86%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.88%-7.58%-25.19%-13.99%+32.44%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
+0.67%-29.86%-34.31%-19.68%-36.17%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.72
Moderate Buy$31.1381.95% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.80
Moderate Buy$87.2244.38% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.46
Hold$110.1720.60% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.56
Moderate Buy$28.10182.41% Upside

Current Analyst Ratings Breakdown

Latest ACAD, SMMT, HALO, and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Set Price Target$130.00
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Boost Price TargetNeutral$79.00 ➝ $81.00
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy$130.00
11/18/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Lower Price TargetMarket Perform$23.00 ➝ $21.00
11/18/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Lower Price TargetMarket Perform$23.00 ➝ $21.00
11/18/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
DowngradeMarket Perform ➝ Underperform$11.90 ➝ $8.30
11/16/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetBuy$43.00 ➝ $42.00
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetEqual Weight$20.00 ➝ $18.00
11/15/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingBuy
11/13/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Lower Price TargetEqual Weight$28.00 ➝ $24.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.20B2.46$0.85 per share20.10$8.03 per share2.13
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.63$2.81 per share21.53$32.30 per share1.87
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B7.46$4.55 per share20.08($0.48) per share-190.31
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.71 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.118.1115.84N/A30.13%8.90%6.86%N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M-$0.10N/A11.750.82-0.52%5.58%3.51%N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.9323.249.320.3626.93%751.81%23.84%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.07N/AN/AN/AN/A-138.82%-117.11%N/A

Latest ACAD, SMMT, HALO, and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$2.30$2.39+$0.09$2.01$491.63 million$492.97 million
11/4/2026Q3 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.1992$0.31+$0.1108$0.31$332.58 million$342.30 million
11/2/2026Q3 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-$0.0493$0.23+$0.2793-$0.63$1.02 billion$1.02 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.82
3.70
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.44
1.32
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
3.88
3.60
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.99
5.99

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
798172.83 million127.55 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.70 million192.38 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423114.01 million111.16 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.76 million145.56 millionOptionable

Recent News About These Companies

Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8% on Analyst Downgrade
Summit Therapeutics (SMMT) Gets a Hold from Barclays
Summit Therapeutics (SMMT) Is Losing Wall Street’s Confidence
Summit Therapeutics (SMMT) Hits 52-Week Low After FDA Setback
2 Cancer-Drug Developers Seeing Unusual Options Volume
Summit and Akeso shares plunge after FDA rejects ivonescimab

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$17.11 -0.48 (-2.73%)
Closing price 04:00 PM Eastern
Extended Trading
$17.07 -0.04 (-0.23%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$60.41 -1.01 (-1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$60.44 +0.03 (+0.04%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$91.35 -1.69 (-1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$91.40 +0.05 (+0.05%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$9.95 -0.62 (-5.87%)
Closing price 04:00 PM Eastern
Extended Trading
$10.09 +0.14 (+1.44%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.